Janney Montgomery Scott LLC Sells 15,218 Shares of AVANOS MEDICAL, INC. (NYSE:AVNS)

Janney Montgomery Scott LLC reduced its position in shares of AVANOS MEDICAL, INC. (NYSE:AVNS) by 43.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,446 shares of the company’s stock after selling 15,218 shares during the quarter. Janney Montgomery Scott LLC’s holdings in AVANOS MEDICAL were worth $279,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. T. Rowe Price Investment Management Inc. boosted its holdings in shares of AVANOS MEDICAL by 27.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after buying an additional 644,267 shares during the last quarter. Brown Advisory Inc. increased its holdings in shares of AVANOS MEDICAL by 12.0% in the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after buying an additional 204,218 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of AVANOS MEDICAL by 43.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock worth $7,874,000 after buying an additional 148,902 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of AVANOS MEDICAL by 189.8% during the fourth quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after buying an additional 132,063 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in AVANOS MEDICAL by 87.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 273,251 shares of the company’s stock valued at $4,350,000 after acquiring an additional 127,591 shares during the period. 95.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of AVANOS MEDICAL from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

AVANOS MEDICAL Trading Down 0.2%

NYSE:AVNS opened at $12.35 on Friday. AVANOS MEDICAL, INC. has a 52 week low of $11.75 and a 52 week high of $25.36. The firm has a 50 day moving average of $12.46 and a 200 day moving average of $14.14. The company has a quick ratio of 1.56, a current ratio of 2.57 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $571.06 million, a price-to-earnings ratio of -1.48 and a beta of 1.12.

AVANOS MEDICAL (NYSE:AVNS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. The business had revenue of $167.50 million for the quarter, compared to analyst estimates of $161.75 million. AVANOS MEDICAL had a negative net margin of 55.80% and a positive return on equity of 6.26%. AVANOS MEDICAL’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.22 EPS. As a group, sell-side analysts anticipate that AVANOS MEDICAL, INC. will post 1.32 earnings per share for the current fiscal year.

AVANOS MEDICAL Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.